news
New lipid nanoparticles effectively deliver RNA to microglia
LNPs deliver small interfering RNA to the brain’s microglia to combat inflammation related to Alzheimer’s disease.
List view / Grid view
Drug Delivery
Drug delivery refers to approaches for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.
article
Women in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
news
Synthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
news
Explosive cell death: inflammation-causing gene
WEHI researchers have found that a genetic change of MLKL increases risk of uncontrolled inflammatory response
webinar
Complete aggregate and particle characterisation of protein, gene and cell therapies
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
article
Antibody-drug conjugates payloads: then, now and next
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.
article
Addressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
article
Therapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
news
Breakthrough treatment defeats deadly fungus
Researchers at the RIKEN Center for Sustainable Research Science (CSRS) and the University of Toronto have discovered a method to combat fungal infections by targeting their fatty acid production.
news
Cracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
article
Precision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
whitepaper
Beyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
article
The future of central nervous system research
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain…
article
Rare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
article
Epigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
